Mereo Biopharma shares rise 1.16% after-hours as Pomerantz Law Firm investigates claims on behalf of investors.

Mereo Biopharma Group Plc rose 1.16% in after-hours trading, following the announcement of a class action investigation by Pomerantz Law Firm into potential securities fraud or other unlawful business practices by the company and its officers or directors. The investigation was initiated after Mereo and its development partner Ultragenyx Pharmaceutical Inc. issued a press release on July 9, 2025, announcing the results of the Phase 3 portion of the Orbit study evaluating UX143 (setrusumab).